Free Trial
→ AI Microcap Teams With Gentex on Next-Gen Military Helmets (From Capital Trends) (Ad)tc pixel Free BCT Stock Alerts

BriaCell Therapeutics (BCT) Competitors

BriaCell Therapeutics logo
C$5.38 -0.23 (-4.10%)
As of 10:08 AM Eastern
Compare

BCT vs. COV, SCYB, COM, NVH, and HBP

Should you buy BriaCell Therapeutics stock or one of its competitors? BriaCell Therapeutics's main competitors and comparable companies include Covalon Technologies (COV), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), and Helix BioPharma (HBP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BriaCell Therapeutics compare to Covalon Technologies?

BriaCell Therapeutics (TSE:BCT) and Covalon Technologies (CVE:COV) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Covalon Technologies has higher revenue and earnings than BriaCell Therapeutics. BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Covalon Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A
Covalon TechnologiesC$34.35M3.27C$2.39MC$0.1625.44

0.0% of BriaCell Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Covalon Technologies shares are held by institutional investors. 9.3% of BriaCell Therapeutics shares are held by company insiders. Comparatively, 48.7% of Covalon Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, BriaCell Therapeutics' average media sentiment score of 0.00 equaled Covalon Technologies'average media sentiment score.

Company Overall Sentiment
BriaCell Therapeutics Neutral
Covalon Technologies Neutral

Covalon Technologies has a net margin of 12.78% compared to BriaCell Therapeutics' net margin of 0.00%. Covalon Technologies' return on equity of 15.04% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A -147.92% -122.71%
Covalon Technologies 12.78%15.04%-3.25%

BriaCell Therapeutics has a beta of 1.883298, suggesting that its share price is 88% more volatile than the broader market. Comparatively, Covalon Technologies has a beta of 0.939041, suggesting that its share price is 6% less volatile than the broader market.

Summary

Covalon Technologies beats BriaCell Therapeutics on 9 of the 10 factors compared between the two stocks.

How does BriaCell Therapeutics compare to Scythian Biosciences?

Scythian Biosciences (CVE:SCYB) and BriaCell Therapeutics (TSE:BCT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scythian BiosciencesN/AN/AN/AN/AN/A
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A

Scythian Biosciences' return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Scythian BiosciencesN/A N/A N/A
BriaCell Therapeutics N/A -147.92%-122.71%

0.0% of BriaCell Therapeutics shares are held by institutional investors. 9.3% of BriaCell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Scythian Biosciences' average media sentiment score of 0.00 equaled BriaCell Therapeutics'average media sentiment score.

Company Overall Sentiment
Scythian Biosciences Neutral
BriaCell Therapeutics Neutral

Summary

Scythian Biosciences and BriaCell Therapeutics tied by winning 2 of the 4 factors compared between the two stocks.

How does BriaCell Therapeutics compare to 138267 (COM.TO)?

138267 (COM.TO) (TSE:COM) and BriaCell Therapeutics (TSE:BCT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

In the previous week, 138267 (COM.TO)'s average media sentiment score of 0.00 equaled BriaCell Therapeutics'average media sentiment score.

Company Overall Sentiment
138267 (COM.TO) Neutral
BriaCell Therapeutics Neutral

0.0% of BriaCell Therapeutics shares are held by institutional investors. 9.3% of BriaCell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

138267 (COM.TO)'s return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
138267 (COM.TO)N/A N/A N/A
BriaCell Therapeutics N/A -147.92%-122.71%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
138267 (COM.TO)N/AN/AN/AN/AN/A
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A

Summary

138267 (COM.TO) and BriaCell Therapeutics tied by winning 2 of the 4 factors compared between the two stocks.

How does BriaCell Therapeutics compare to Novoheart?

BriaCell Therapeutics (TSE:BCT) and Novoheart (CVE:NVH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

0.0% of BriaCell Therapeutics shares are owned by institutional investors. 9.3% of BriaCell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

BriaCell Therapeutics has higher earnings, but lower revenue than Novoheart. Novoheart is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A
NovoheartC$423.50K236.08-C$7.17M-C$0.04N/A

In the previous week, BriaCell Therapeutics' average media sentiment score of 0.00 equaled Novoheart'saverage media sentiment score.

Company Overall Sentiment
BriaCell Therapeutics Neutral
Novoheart Neutral

Novoheart's return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A -147.92% -122.71%
Novoheart N/A N/A N/A

Summary

BriaCell Therapeutics and Novoheart tied by winning 4 of the 8 factors compared between the two stocks.

How does BriaCell Therapeutics compare to Helix BioPharma?

BriaCell Therapeutics (TSE:BCT) and Helix BioPharma (TSE:HBP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

In the previous week, Helix BioPharma had 1 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for BriaCell Therapeutics. BriaCell Therapeutics' average media sentiment score of 0.00 equaled Helix BioPharma'saverage media sentiment score.

Company Overall Sentiment
BriaCell Therapeutics Neutral
Helix BioPharma Neutral

Helix BioPharma's return on equity of -21.54% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A -147.92% -122.71%
Helix BioPharma N/A -21.54%-279.98%

Helix BioPharma is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A

0.0% of BriaCell Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of Helix BioPharma shares are owned by institutional investors. 9.3% of BriaCell Therapeutics shares are owned by company insiders. Comparatively, 2.2% of Helix BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

BriaCell Therapeutics has a beta of 1.883298, meaning that its stock price is 88% more volatile than the broader market. Comparatively, Helix BioPharma has a beta of 1.154669, meaning that its stock price is 15% more volatile than the broader market.

Summary

BriaCell Therapeutics beats Helix BioPharma on 6 of the 9 factors compared between the two stocks.

Get BriaCell Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCT vs. The Competition

Export
MetricBriaCell TherapeuticsBiotechnology IndustryHealthcare SectorTSE Exchange
Market CapC$46.81MC$3.88BC$7.26BC$12.69B
Dividend Yield13.70%3.65%2.52%6.34%
P/E Ratio-6.4013.21275.5437.73
Price / SalesN/A1,131.68557.678.56
Price / CashN/A118.5077.1682.29
Price / Book1.6717.1610.814.40
Net Income-C$2.37M-C$22.65MC$3.49BC$299.09M
7 Day Performance-5.45%-4.64%-3.00%0.29%
1 Month Performance8.03%-12.66%-7.48%-1.77%
1 Year Performance-66.23%8.08%3.18%14.81%

BriaCell Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCT
BriaCell Therapeutics
N/AC$5.38
-4.1%		N/A-69.1%C$46.81MN/AN/A17
COV
Covalon Technologies
N/AC$3.82
-5.7%		N/A+102.5%C$105.50MC$34.35M23.88105
SCYB
Scythian Biosciences
N/AC$3.49
-5.9%		N/A+0.0%C$102.38MN/AN/AN/A
COM
138267 (COM.TO)
N/AN/AN/AN/AC$102.19MN/AN/AN/A
NVH
Novoheart
N/AC$0.53
+1.9%		N/A+0.0%C$99.98MC$423.50KN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:BCT) was last updated on 10/14/2026 by MarketBeat.com Staff.
From Our Partners
Wall Street legend reveals his top AI stock before Oct. 20
Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...
Chaikin Analytics | Sponsoredtc pixel
Trump's about to unleash his Midterm Weapon
Trump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...
Monument Traders Alliance | Sponsoredtc pixel
Elon Musk’s One Stock Retirement Plan
Jeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...
Brownstone Research | Sponsoredtc pixel
How one AI fund pays investors every Thursday
One small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...
Investors Alley | Sponsoredtc pixel
The Iran War Isn’t Chaos. It’s Strategy.
Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...
Behind the Markets | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Forget Biotech Stocks… This Is the Smarter Play
NVIDIA, Shopify, and TSMC built fortunes by powering innovation rather than betting on a single winner. One li...
Compounding Quality | Sponsoredtc pixel